Corbus Pharmaceuticals Statistics
Share Statistics
Corbus Pharmaceuticals has 12.23M
shares outstanding. The number of shares has increased by 14.46%
in one year.
| Shares Outstanding | 12.23M |
| Shares Change (YoY) | 14.46% |
| Shares Change (QoQ) | 0.43% |
| Owned by Institutions (%) | 0% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 2,929 |
| FTD / Avg. Volume | 1.26% |
Short Selling Information
The latest short interest is 2.14M, so 17.48% of the outstanding
shares have been sold short.
| Short Interest | 2.14M |
| Short % of Shares Out | 17.48% |
| Short % of Float | 21.78% |
| Short Ratio (days to cover) | 10.81 |
Valuation Ratios
The PE ratio is -3.2 and the forward
PE ratio is -1.55.
Corbus Pharmaceuticals's PEG ratio is
0.05.
| PE Ratio | -3.2 |
| Forward PE | -1.55 |
| PS Ratio | 0 |
| Forward PS | 0.6 |
| PB Ratio | 0.9 |
| P/FCF Ratio | -3.08 |
| PEG Ratio | 0.05 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Corbus Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.94,
with a Debt / Equity ratio of 0.02.
| Current Ratio | 12.94 |
| Quick Ratio | 12.94 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.08 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,436,035.71 |
| Employee Count | 28 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -80.26% in the
last 52 weeks. The beta is 3.13, so Corbus Pharmaceuticals's
price volatility has been higher than the market average.
| Beta | 3.13 |
| 52-Week Price Change | -80.26% |
| 50-Day Moving Average | 6.52 |
| 200-Day Moving Average | 22.47 |
| Relative Strength Index (RSI) | 59.96 |
| Average Volume (20 Days) | 232,260 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | n/a |
| Net Income | -40.21M |
| EBITDA | n/a |
| EBIT | n/a |
| Earnings Per Share (EPS) | -3.68 |
Full Income StatementBalance Sheet
The company has 17.2M in cash and 3.24M in
debt, giving a net cash position of 13.96M.
| Cash & Cash Equivalents | 17.2M |
| Total Debt | 3.24M |
| Net Cash | 13.96M |
| Retained Earnings | -476.89M |
| Total Assets | 155.88M |
| Working Capital | 141.16M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -41.79M
and capital expenditures 0, giving a free cash flow of -41.79M.
| Operating Cash Flow | -41.79M |
| Capital Expenditures | n/a |
| Free Cash Flow | -41.79M |
| FCF Per Share | -3.83 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
